| VARIABLES |
IRAQI Patients N = 635 (%) |
BRITISH Patients N = 1,305 (%) | Chi square Test P value |
|---|---|---|---|
| ESTROGEN RECEPTOR | N = 561 | N = 1272 | < .00001 |
| Positive | 388 (69.2) | 1100 (86.5) | |
| Negative | 173 (30.8) | 172 (13.5) | |
| Unknown | 74 | 33 | |
| PROGESTERONE RECEPTOR | N = 561 | N = 543 | . < .00001 |
| Positive | 374 (66.7) | 433 (79.7) | |
| Negative | 187 (33.3) | 110 (20.3) | |
| Unknown | 74 | 33 | |
| HER2 STATUS | N = 541 | N = 1138 | < .00001 |
| Positive | 158 (29.2) | 143 (12.6) | |
| Negative | 383 (70.8) | 995 (87.4) | |
| Unknown | 94 | 167 | |
| BREAST CANCER SUBTYPES | N = 532 | N = 441 | < .00001 |
| Luminal A (E+/P+/HER2-) | 252 (47.4) | 325 (73.7) | |
| Luminal B (E+/P+/HER2+) | 73 (13.7) | 31 (7.0) | |
| HER2 Enriched (E-/P-/HER2+) | 57 (10.7) | 11 (2.5) | |
| Triple Negative (E-/P-/HER2-) | 78 (14.7) | 22 (5.0) | |
| Others | 72 (13.5) | 52 (11.8) |